CENZILEUCEL
UNII Q5KB23UV6Q

Substance Identification & Data

This profile provides standardized clinical and technical data for Cenzileucel, uniquely identified by the FDA Unique Ingredient Identifier (UNII) Q5KB23UV6Q.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number N/A and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

Q5KB23UV6Q

CAS Registry Number

N/A

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

CENZILEUCEL

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C203191

National Cancer Institute reference terminology for clinical and research data.

INN ID

12313

Sequential identifier assigned via the WHO International Nonproprietary Name program.

Substance Type

structurallyDiverse

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

ITIS TSN

180092

Taxonomic Serial Number for species identified in the Integrated Taxonomic Information System.

NCBI Taxonomy

9606

Unique numeric identifier used to specify biological species in the NCBI database.

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Cenzileucel. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

CENZILEUCEL

Common Names & Synonyms

CENZILEUCEL [INN]

HUMAN CULTURE-EXPANDED ACTIVATED AUTOLOGOUS T LYMPHOCYTES FOR CELL-BASED IMMUNOTHERAPY. THE CELLS ARE MECHANICALLY AND ENZYMATICALLY ISOLATED FROM RESECTED TUMOUR BIOPSY OF PATIENTS WITH METASTATIC MELANOMA AND CULTURED IN MEDIA CONTAINING RECOMBINANT INTERLEUKIN 2 (IL-2) AND FOETAL BOVINE SERUM (FBS). THE CELLS ARE ACTIVATED USING AN ANTI-CD3 ANTIBODY AND IRRADIATED ALLOGENEIC PERIPHERAL-BLOOD MONONUCLEAR CELLS (PBMCS) IN MEDIA SUPPLEMENTED WITH HUMAN AB DONOR DERIVED SERUM AND IL-2. THE T LYMPHOCYTES (>80%) ARE A HETEROGENEOUS MIXTURE OF CD4+ AND CD8+ TUMOUR-INFILTRATING LYMPHOCYTES (TIL) PREDOMINANTLY WITH EFFECTOR MEMORY AND CENTRAL MEMORY CELL SUBSETS. THE T LYMPHOCYTES DEMONSTRATE THE ABILITY TO KILL AND IMPEDE TUMOUR GROWTH IN A CO-CULTURE BASED CYTOTOXICITY ASSAY

External Clinical & Regulatory Resources

Previous UNIIQ5K7HYS7JJ

Next UNIIQ5KH60X1LL